Table 3 Adverse reactions under RIT (all patients)
°III allergic reaction leading to discontinuation of cetuximab | 4 pts (5,6%) |
Skin reactions leading to cetuximab breaks | 1 pt (1,4%) |
Skin reactions leading to discontinuation of cetuximab | 3 pts (4,2%) |
Overall °III skin reactions | 6 pts (8,3%) |
Discontinuation of treatment due to detoriation of overall condition | 5 pts (6,9%) |